On this page
hydrocortisone
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 089074-001 | STIE-CORT | LOTION | HYDROCORTISONE | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 15 | Labeling | Approved | November 28, 2007 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | August 16, 2001 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | August 3, 1998 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | January 17, 1996 | — |
| Supplement | 9 | Labeling | Approved | January 17, 1996 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | September 14, 1995 | — |
| Supplement | 8 | Labeling | Approved | September 14, 1995 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | September 14, 1995 | — |
| Supplement | 11 | Manufacturing (CMC) | Approved | April 14, 1995 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | May 14, 1986 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | May 14, 1986 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | April 11, 1986 | — |
| Original application | 1 | Approved | November 26, 1985 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260825). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingUses For the temporary relief associated with minor skin irritations, inflammation and rashes due to: eczema seborrheic dermatitis psoriasis insect bites poison ivy, oak, sumac soaps detergents cosmetics jewelry external genital and anal itching. Other uses of this product should be only under the advice and supervision of a doctor.
Purpose
openFDA Drug LabelingPurpose Antipruritic (Anti-itch)
Dosage and Administration
openFDA Drug LabelingDirections Adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily Children under 2 years of age: do not use, consult a doctor For External Anal Itching Users adults: when practical, cleanse the affected area with mild soap and warm water and rinse thoroughly, and gently dry by patting or blotting with toilet tissue or a soft cloth before application of this product children under 12 years of age: consult a doctor
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Warnings and Cautions
openFDA Drug LabelingRx Only For external use only Not for opthalmic use
Warnings
openFDA Drug LabelingWarnings For external use only avoid contact with the eyes Stop using this product and ask a doctor if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days before you begin using any other hydrocortisone product Do not use this product and ask a doctor if you have a vaginal discharge before treating diaper rash before using on children under 2 years of age For external anal itching users do not exceed the recommended daily dosage unless directed by a doctor in case of bleeding, consult a doctor promptly do not put this product into the rectum by using fingers or any mechanical device or applicator Keep this and all drugs out of the reach of children
Do Not Use
openFDA Drug LabelingDo not use this product and ask a doctor if you have a vaginal discharge before treating diaper rash before using on children under 2 years of age
Ask a Doctor
openFDA Drug LabelingStop use and ask a doctor if • condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor
Stop Use
openFDA Drug LabelingStop use and ask a doctor if Condition worsens If symptoms persist for more than 7 days or clear up and occur again within a few days. Discontinue use of this product and do not begin use of any other hydrocortisone product unless you have consulted a doctor. Do no use for diaper rash. Consult a doctor.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an aproximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermitis, allergic contact dermatis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Allegis Holdings, LLC at 1-866-633-9033 or FDA at 1-800-FDA-1088 or https://fda.gov/Safety/MedWatch/
Description
openFDA Drug LabelingDESCRIPTION Each mL of Hydrocortisone Lotion USP, 2.5% contains 25 mg of hydrocortisone, USP in a vehicle consisting of carbomer homopolymer type C, ceteareth-20, cetyl alcohol, dehydroacetic acid, DMDM hydantoin, fragrance, glyceryl stearate, isopropyl palmitate, lactic acid, light mineral oil, myristyl alcohol, myristyl lactate, PEG-100 stearate, purified water, sodium hydroxide, sodium PCA, and stearyl alcohol. Chemically, hydrocortisone is [Pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-, (11ß)-] with the molecular formula C 21 H 30 O 5 and is represented by the following structural formula: Its molecular weight is 362.46 and its CAS Registry Number is 50-23-7. The topical corticosteroids, including hydrocortisone, constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. chemical structure.png
Active Ingredient
openFDA Drug LabelingActive Ingredient Hydrocortisone 1% (Micronized)
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Hydrocortisone Lotion USP, 2.5% is available as follow: NDC: 72162-1441-4: 2 fl oz (59 mL) in a BOTTLE NDC: 72162-1441-7: 4 fl oz (118 mL) in a BOTTLE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Keep tightly closed. Keep out of the reach of children. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 71399-0120-1 | 71399-0120 | AKRON PHARMA INC | 1 BOTTLE in 1 CARTON (71399-0120-1) / 120 mL in 1 BOTTLE | September 13, 2024 |
| 71297-010-01 | 71297-010 | Allegis Holdings LLC | 1 BOTTLE, WITH APPLICATOR in 1 BOX (71297-010-01) / 29.6 mL in 1 BOTTLE, WITH APPLICATOR | June 10, 2024 |
| 71297-010-02 | 71297-010 | Allegis Holdings LLC | 1 BOTTLE, WITH APPLICATOR in 1 BOX (71297-010-02) / 59.2 mL in 1 BOTTLE, WITH APPLICATOR | June 10, 2024 |
| 72288-469-25 | 72288-469 | Amazon.com Services LLC | 1 TUBE in 1 CARTON (72288-469-25) / 99 g in 1 TUBE (72288-469-00) | August 25, 2026 |
| 63629-2529-1 | 63629-2529 | Bryant Ranch Prepack | 118 mL in 1 BOTTLE (63629-2529-1) | May 23, 2008 |
| 63629-8668-1 | 63629-8668 | Bryant Ranch Prepack | 59 mL in 1 BOTTLE (63629-8668-1) | September 24, 2008 |
| 63629-9416-1 | 63629-9416 | Bryant Ranch Prepack | 118 mL in 1 BOTTLE (63629-9416-1) | August 23, 2022 |
| 71335-2918-1 | 71335-2918 | Bryant Ranch Prepack | 118 mL in 1 BOTTLE (71335-2918-1) | October 28, 2025 |
| 72162-1441-4 | 72162-1441 | Bryant Ranch Prepack | 59 mL in 1 BOTTLE (72162-1441-4) | February 8, 2024 |
| 72162-1441-7 | 72162-1441 | Bryant Ranch Prepack | 118 mL in 1 BOTTLE (72162-1441-7) | February 8, 2024 |
| 0394-0859-32 | 0394-0859 | Mericon Industries | 12 BOTTLE, DISPENSING in 1 BOX (0394-0859-32) / 114 g in 1 BOTTLE, DISPENSING | June 12, 2023 |
| 45802-937-16 | 45802-937 | Padagis Israel Pharmaceuticals Ltd | 59 mL in 1 BOTTLE (45802-937-16) | September 24, 2008 |
| 45802-937-26 | 45802-937 | Padagis Israel Pharmaceuticals Ltd | 118 mL in 1 BOTTLE (45802-937-26) | May 23, 2008 |
| 71399-0120 | 71399-0120 | AKRON PHARMA INC | — | September 13, 2024 |
| 71297-010 | 71297-010 | Allegis Holdings LLC | — | June 10, 2024 |
| 72288-469 | 72288-469 | Amazon.com Services LLC | — | August 25, 2026 |
| 63629-2529 | 63629-2529 | Bryant Ranch Prepack | — | May 23, 2008 |
| 63629-8668 | 63629-8668 | Bryant Ranch Prepack | — | May 23, 2008 |
| 63629-9416 | 63629-9416 | Bryant Ranch Prepack | — | May 23, 2008 |
| 71335-2918 | 71335-2918 | Bryant Ranch Prepack | — | May 23, 2008 |
| 72162-1441 | 72162-1441 | Bryant Ranch Prepack | — | May 23, 2008 |
| 0394-0859 | 0394-0859 | Mericon Industries | — | June 12, 2023 |
| 45802-937 | 45802-937 | Padagis Israel Pharmaceuticals Ltd | — | May 23, 2008 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.